Clinical Trials for Relapsed Cancer
Advancing Childhood Cancer Therapies (ACCT) Clinic
For patients with relapsed, refractory, or recurrent cancer, early phase clinical trials may be a treatment option. Phase I and phase II clinical trials provide access to the newest, most innovative therapies to patients.
The Advancing Childhood Cancer Therapies (ACCT) Clinic is dedicated to
offering state-of-the-art therapies, advancing the science of pediatric
research, and providing personalized care to you and your family. The Clinic includes experts in each type of cancer as well as teams of subspecialists and nurses who are leaders in their respective fields. In August 2016, we joined the Children’s Oncology Group Phase 1 Consortium, one of only 21 such centers in the United States and the only one in New England.
Our currently active phase I and phase II trials for patients with relapsed, recurrent, or refractory cancer are listed below by disease – or search all of our available clinical trials.
If you have questions about which trial might be right for your child or patient, please email us at clinicaltrials@danafarberbostonchildrens.org or call us at 1-855-320-2090. We can help you navigate your options.
Phase I and II Trials for Relapsed and Refractory Cancer
- A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
Principal Investigator Susan Chi, MD
- A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
Principal Investigator Karen Wright, MD
- Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive relapsed or refractory High-Grade Glioma (HGG)
Principal Investigator Karen Wright, MD
- A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects
Principal Investigator Susan Chi, MD
- PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
Principal Investigator Susan Chi, MD
- A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors As A Single Agent and in Combination with Temozolomide and Irinotecan
Principal Investigator Steven DuBois, MD
- Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Principal Investigator Suzanne Shusterman, MD
- A Phase I Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory
Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Principal Investigator Steven DuBois, MD
- A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1 Trial of CUDC-907 in Children and
Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or
Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase I/II Study of Pembrolizumab
(MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced,
relapsed or refractory solid tumor or lymphoma
Principal Investigator Steven DuBois, MD
- PNOC 002: Safety, Phase 0, and Pilot
Efficacy Study of Vemurafenib, an oral inhibitor of BRAFV600E, in Children
and Young Adults with Recurrent/Refractory BRAFV600E or BRAF Ins T mutant
Brain Tumors
Principal Investigator Susan Chi, MD
- A Phase 1 Study of Selinexor (KPT-330), a
Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid
Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD
- A Phase I/II, Multicenter, Open-Label,
Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in
Pediatric and Young Adult Patients with Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase I Study of the EZH2 Inhibitor
Tazemetostat in Pediatric Subjects with Relapsed or Refractory
INI1-Negative Tumors or Synovial Sarcoma
Principal Investigator Susan Chi, MD
- A Phase II Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapse or Refractory Synovial Sarcoma
Principal Investigator Gregory Cote, MD
- Phase I-II Study of MEK162 for Children
Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
Principal Investigator Karen Wright, MD
- Phase I Open Label, Dose Escalation,
Monotherapy Trial of Afatinib to Determine the MTD, Safety, PK and
Efficacy of Afatinib in Children Aged 2 Years to <18 Years with
Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and Tumours
with ErbB Pathway Deregulation
Principal Investigator Karen Wright, MD
- Open-label, Phase 2 Study of Bevacizumab in
Children and Adults with Neurofibromatosis 2 and Progressive Vestibular
Schwannomas That Are Poor Candidates for Standard Treatment with Surgery
or Radiation
Principal Investigator Nicole Ullrich, MD
- PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Glioma in Children
Principal Investigator Susan Chi, MD
- A Phase II Study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma
Principal Investigator Susan Chi, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
- A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Principal Investigator Steven DuBois, MD
- A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Principal Investigator Andrew Place, MD
- A Phase 1/2 Study of Nivolumab in Children,
Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a
Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Principal Investigator Steven DuBois, MD
- Phase 1 Trial of CUDC-907 in Children and Young
Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase I/II Study of Pembrolizumab (MK-3475) in
Children with advanced melanoma or a PD-L1 positive advanced, relapsed or
refractory solid tumor or lymphoma
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of Selinexor (KPT-330), a
Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors,
Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD
- Phase I Study of Carfilzomib in Combination with
Cyclophosphamide and Etoposide for Children with Relapsed and Refractory Solid
Tumors and Leukemias
Principal Investigator Steven DuBois, MD
- An Open-Label, Dose-Escalation, Phase I/II Study
to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical
Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects
with Cancer or Plexiform Neurofibromas and Trametinib in Combination with
Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Karen Wright, MD
- A Phase I Trial of Temsirolimus in Combination
with Etoposide and Cyclophosphamide in Children with Relapsed Acute
Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Principal Investigator Lewis Silverman, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
- NANT 2017-01: A Phase I Study Of 131I-MIBG With Dinutuximab For Relapsed/Refractory Neuroblastoma
Principal Investigator Suzanne Shusterman, MD
- NANT 2015-02: Phase 1 Study Of Lorlatinib (PF-06463922), An Oral Small Molecule Inhibitor Of ALK/ROS1, For Patients With ALK-Driven Relapsed Or Refractory Neuroblastoma
Principal Investigator Suzanne Shusterman, MD
- A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Principal Investigator Andrew Place, MD
- A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD, MS
- A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Principal Investigator Steven DuBois, MD, MS
- A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD
- A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase 1/1b, Open-Label, Dose-Escalation
and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents
with Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD
- Phase I
Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide
for Children with Relapsed and Refractory Solid Tumors and Leukemias
Principal Investigator Steven DuBois, MD
- A Phase
I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and
Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with
Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD
- Phase I
Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine
the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to
<18 Years with Recurrent/Refractory Neuroectodermal Tumours,
Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
Principal Investigator Mark Kieran, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
- A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Principal Investigator: Steven DuBois, MD
- Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Principal Investigator: Steven DuBois, MD
- A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
Principal Investigator: Susan Chi, MD
- A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors As A Single Agent and in Combination with Temozolomide and Irinotecan
Principal Investigator Steven DuBois, MD
- Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Principal Investigator Suzanne Shusterman, MD
- A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Principal Investigator Andrew Place, MD
- A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Principal Investigator Steven DuBois, MD
- Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma
Principal Investigator Steven DuBois, MD
- A Phase II Study of Pazopanib (GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors
Principal Investigator Suzanne Shusterman, MD
- A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD, MS
- A Phase
1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with
Recurrent or Refractory Solid Tumors as a Single Agent and in Combination
with Ipilimumab
Principal Investigator Steven DuBois, MD
- A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1
Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory
Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase
I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma
or a PD-L1 positive advanced, relapsed or refractory solid tumor or
lymphoma
Principal Investigator Steven DuBois, MD
- A Phase
1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib
(RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid
Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD
- Phase I
Study of Carfilzomib in Combination with Cyclophosphamide and Etoposide
for Children with Relapsed and Refractory Solid Tumors and Leukemias
Principal Investigator Steven DuBois, MD
- A Phase
I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and
Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with
Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase
1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor,
in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Principal Investigator Suzanne Shusterman, MD
- Phase I
Open Label, Dose Escalation, Monotherapy Trial of Afatinib to Determine
the MTD, Safety, PK and Efficacy of Afatinib in Children Aged 2 Years to
<18 Years with Recurrent/Refractory Neuroectodermal Tumours,
Rhabdomyosarcoma and Tumours with ErbB Pathway Deregulation
Principal Investigator Karen Wright, MD
- An
Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety,
Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK
Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or
Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in
Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Karen Wright, MD
- Phase I Study of Olaparib with Irinotecan
and/or Temezolomide in Adolescent and Adult Patients with
Recurrent/Metastatic Ewing’s Sarcoma Following Failure of Prior
Chemotherapy
Principal Investigator Steven
DuBois, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.
- A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Principal Investigator: Steven DuBois, MD
- Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Principal Investigator: Steven DuBois, MD
- A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
Principal Investigator: Susan Chi, MD
- A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1 Trial of The LSD1 Inhibitor SP-2577 In Patients with Relapsed or Refractory Ewing Sarcoma
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) In Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors As A Single Agent and in Combination with Temozolomide and Irinotecan
Principal Investigator Steven DuBois, MD
- Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Principal Investigator Suzanne Shusterman, MD
- A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
Principal Investigator Andrew Place, MD
- A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers
Principal Investigator Steven DuBois, MD
- Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma
Principal Investigator Steven DuBois, MD
- A Phase II Study of Pazopanib (GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors
Principal Investigator Suzanne Shusterman, MD
- A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
Principal Investigator Steven DuBois, MD, MS
- Phase 1/2 Study of Nivolumab in Children,
Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a
Single Agent and in Combination with Ipilimumab
Principal Investigator Steven DuBois, MD
- A Phase 1/2 Study of AZD1775 (MK-1775) In Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
Principal Investigator Steven DuBois, MD
- Phase 1 Trial of CUDC-907 in Children and Young
Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase I/II Study of Pembrolizumab (MK-3475) in
Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or
Refractory Solid Tumor or Lymphoma
Principal Investigator Steven DuBois, MD
- A Phase 1/1b, Open-Label, Dose-Escalation and
Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with
Recurrent or Refractory Solid Tumors and Primary CNS Tumors
Principal Investigator Steven DuBois, MD
- A Phase 1 Study of Selinexor, a Selective XPO1
Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS
Tumors
Principal Investigator Suzanne Shusterman, MD
- A Phase
I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and
Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with
Previously Treated Solid Tumors
Principal Investigator Steven DuBois, MD
- A Phase II Study of the EZH2 Inhibitor
Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapse or
Refractory Synovial Sarcoma
Principal Investigator Gregory Cote, MD
- A Phase I Study of the EZH2 Inhibitor
Tazemetostat in Pediatric Subjects with Relapse or Refractory INI1-Negative
Tumors or Synovial Sarcoma
Principal Investigator Susan Chi, MD
- An Open-Label, Dose-Escalation, Phase I/II Study
to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical
Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects
with Cancer or Plexiform Neurofibromas and Trametinib in Combination with
Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
Principal Investigator Karen Wright, MD
- Phase I Study of Olaparib with Irinotecan and/or
Temozolomide in Adolescent and Adult Patients with Recurrent/Metastatic Ewing's
Sarcoma Following Failure of Prior Chemotherapy
Principal Investigator Steven DuBois, MD
Contact us
Not sure which clinical trials might be right for your child? Email our clinical trials team at clinicaltrials@danafarberbostonchildrens.org.